FDA rejects Covid-19 drug over uncertainties around small trial

Following the advice of a panel of outside experts, the FDA has turned down a potential Covid-19 drug that only had data from a small trial.

Miami, FL-based Veru had repurposed a microtubule disruptor called sabizabulin, which it had been testing in cancer, to treat hospitalized adult patients with moderate to severe Covid-19 who are at high risk for ARDS, or acute respiratory distress syndrome.